Matrixx Projects Profit, But Zicam Litigation "Storm Clouds" Could Still Rain
This article was originally published in The Tan Sheet
Executive Summary
Matrixx Initiatives believes it has emerged with a plan for returning to growth and profitability after navigating the gauntlet of an FDA warning, product recall and millions in lost revenue in fiscal 2010
You may also be interested in...
Matrixx Prompts Supreme Court To Consider What Firms Must Disclose
A class action suit against Zicam Cold Remedy maker Matrixx Initiatives heads to the Supreme Court, in a case that could affect the number of securities actions brought against pharma companies
Matrixx Prompts Supreme Court To Consider What Firms Must Disclose
A class action suit against Zicam Cold Remedy maker Matrixx Initiatives heads to the Supreme Court, in a case that could affect the number of securities actions brought against pharma companies
Matrixx Prompts Supreme Court To Consider What Firms Must Disclose
A class action suit against Zicam Cold Remedy maker Matrixx Initiatives heads to the Supreme Court, in a case that could affect the number of securities actions brought against pharma companies